Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00938-z
Abstract: The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to… read more here.
Keywords: baricitinib; tofacitinib baricitinib; drug; baricitinib upadacitinib ... See more keywords
AB0492 Jak-inhibition with peficitinib and filgotinib in fibroblast-like synoviocytes in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2182
Abstract: Background With the approval of the Janus kinase inhibitors (JAKi) Tofacitinib and Baricitinib for the treatment of rheumatoid arthritis (RA) in the European Union (EU), the opportunities for a successful therapy were extended by a… read more here.
Keywords: peficitinib filgotinib; tofacitinib baricitinib; hour; rheumatoid arthritis ... See more keywords
OP0237 THROMBOEMBOLIC SAFETY PROFILE OF TOFACITINIB AND BARICITINIB: AN ANALYSIS OF WHO VIGIBASE
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2823
Abstract: The Janus Kinase (JAK) inhibitors tofacitinib and baricitinib are new targeted treatments for rheumatoid arthritis. Recent concerns regarding the risk of thrombosis have led to warnings by the European Medicines Agency (EMA) and the Food… read more here.
Keywords: ror; vigibase; risk; baricitinib ... See more keywords
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy.
Sign Up to like & getrecommendations! Published in 2022 at "Reumatismo"
DOI: 10.4081/reumatismo.2022.1511
Abstract: The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients' data,… read more here.
Keywords: safety; month; rheumatoid arthritis; tofacitinib baricitinib ... See more keywords